Dr. Vaishampayan on Checkmate-274 trial of adjuvant nivolumab in bladder cancer

Ulka Nitin Vaishampayan, MBBS, director, Phase I Program, Rogel Cancer Center, Michigan Medicine, professor of internal medicine, University of Michigan, discusses the phase 3 CheckMate-274 trial, which supported the FDA approval of nivolumab (Opdivo) for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection, regardless of prior neoadjuvant chemotherapy, nodal involvement, or PD-L1 status.

In the study, adjuvant nivolumab led to a significant improvement in disease-free survival. Overall survival data are still maturing, explains Vaishampayan.